Introduction
============

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. It is characterized by persistent respiratory symptoms and airflow limitation.[@b1-copd-13-1735] In People's Republic of China, the prevalence of COPD in individuals ≥40 years of age is estimated at 8.2%[@b2-copd-13-1735] or varying from 5% to 13% in different provinces/cities.[@b3-copd-13-1735] Cigarette smoking is considered as the most important risk factor, but genetic characteristics play an important role in the susceptibility to COPD. Genome-wide association studies (GWAS) identified several genomic regions associated with higher COPD risk. Some GWAS loci are located in the *FAM13A* gene on chromosome 4q22 and in the 15q25 locus, which includes the *IREB2* gene.[@b4-copd-13-1735],[@b5-copd-13-1735]

GWAS showed that variants in FAM13A (family with sequence similarity 13, member A) were associated with FEV~1~/FVC and COPD.[@b6-copd-13-1735]--[@b8-copd-13-1735] *FAM13A* was initially considered as a signal transduction gene because of the RhoGAP functional domain in the exon region,[@b9-copd-13-1735] but it is now known to be associated with β-catenin signaling, which is typically activated during injury repair and tissue regeneration.[@b10-copd-13-1735],[@b11-copd-13-1735] Hypoxia commonly accompanies COPD and enhances *FAM13A* expression.[@b9-copd-13-1735] In addition, Kim et al[@b12-copd-13-1735] showed that FAM13A SNPs associated with a higher risk of COPD were also associated with an increased FAM13A expression in the lungs, suggesting a possible causative association with pathological changes in the lung. Corvol et al[@b13-copd-13-1735] showed that the association of the *FAM13A* gene with pulmonary function parameters (FEV~1~%predicted and FEV~1~/FVC) was observed in different independent cohorts, suggesting that FAM13A is associated with a specific phenotype of COPD. Furthermore, Choo et al[@b14-copd-13-1735] demonstrated an association between the CTGA diplotype in FAM13A and the emphysema phenotype of COPD, and Jiang et al[@b11-copd-13-1735] provided the basis for the role of FAM13A in the development of emphysema. A recent study by Corvol et al[@b15-copd-13-1735] showed that FAM13A and airway epithelial-mesenchymal transition (EMT) are closely associated in cystic fibrosis. EMT is also thought to play an important role in airway remodeling in COPD.[@b16-copd-13-1735] Taken together, these results strongly suggest that FAM13A is involved in the etiology of lung diseases and COPD.

Iron is found in cigarette smoke[@b17-copd-13-1735] and has been shown to disrupt the lung homeostasis, making lung tissues more susceptible to damage from any cause.[@b18-copd-13-1735] *IREB2* is a gene that is translated into the iron regulatory protein 2 (IRP2), which plays a key role in iron homeostasis. *IREB2* is in strong linkage disequilibrium with nicotine receptor genes (*CHRNA3* and *5*).[@b5-copd-13-1735] IREB2 expression is increased in the lungs of patients with COPD.[@b19-copd-13-1735] IRP2 regulates cellular iron homeostasis and mitochondrial function.[@b20-copd-13-1735],[@b21-copd-13-1735] It is reported that some IREB2 variants may affect COPD in the presence of high levels of iron due to cigarette smoke exposure.[@b18-copd-13-1735] Therefore, there could be some association between IREB2 and respiratory conditions such as COPD.

The association between single-nucleotide polymorphisms (SNPs) in *FAM13A* and *IREB2* and the risk of COPD is still unclear, although some GWAS loci have been reported.[@b4-copd-13-1735],[@b5-copd-13-1735] We aimed to identify new genetic variants associated with COPD in People's Republic of China. The aim of the present case-control study was to examine the association between tag SNPs[@b22-copd-13-1735] in FAM13A and IREB2 and COPD risk. In addition, this is the first study evaluating the effect of genetic factors on the pathogenesis of COPD in the Ningxia Hui Autonomous Region (Northwest China).

Materials and methods
=====================

Study design and population
---------------------------

The COPD screening and early intervention project in the Ningxia Hui Autonomous Region was funded by the Ningxia government and aimed to carry out a prospective investigation between January 2014 and December 2016 to acquire data on COPD in the Ningxia Hui Autonomous Region. The investigation was approved by the ethics committee of the General Hospital of Ningxia Medical University. All participants provided a written informed consent.

A total of 6,130 participants ≥40 years of age and from a single township volunteered to participate in the study. They were local farmers, and at least three generations of their families were Han.

The participants were grouped as COPD and controls. COPD was defined as post-bronchodilator FEV~1~/FVC \<70% and with chronic respiratory airway symptoms including dyspnea, chronic cough, sputum production, or wheezing. The exclusion criteria were as follows: 1) history of other respiratory diseases such as bronchial asthma, pulmonary tuberculosis, interstitial lung disease, or lung cancer or 2) unable to perform the lung function tests for any reason. The controls were with normal pulmonary function (FEV~1~/FVC \>70%) and had no known medical illnesses or family disorders.

All volunteers underwent blood tests and completed questionnaires. The participants were interviewed by trained interviewers using standardized questionnaires about the risk factors of COPD. All pulmonary function measurements were performed using portable spirometers (MicroLab Spirometer, MD Spiro, Lewiston, ME, USA) and according to the guidelines of the American Thoracic Society.[@b23-copd-13-1735] Peripheral blood samples (2 mL) were collected in EDTA Vacutainer tubes for DNA extraction.

SNP selection and genotyping
----------------------------

We selected seven tag SNPs in the *FAM13A* and *IREB2* genes using the Genome Variation Server database (<http://gvs.gs.washington.edu/GVS147/>) and the National Center for Biotechnology Information database (<http://www.ncbi.nlm.nih.gov/projects/SNP>) and based on the following criteria: tag SNPs in the CHB and Asian database selected by the Haploview 4.2 software (Broad Institute, Cambridge, MA, USA)[@b24-copd-13-1735] with Hardy-Weinberg equilibrium (HWE) *P*-value ≥0.05, a minor allele frequency ≥0.05, and *r*^2^ ≥0.8.

Peripheral blood leukocyte DNA was extracted using a DNA extraction kit (Promega, Madison, WI, USA). DNA concentration was determined using a NanoDrop 1000 (Thermo Fisher Scientific, Waltham, MA, USA). Genotyping was done by CapitalBio Corporation (Beijing, People's Republic of China) using a MassARRAY platform (Agena Biosciences Inc., San Diego, CA, USA), according to the manufacturer's protocol. Multiplex reaction primers were designed using the MassARRAY Assay Design Tools on the Agena official website (<https://agenacx.com/online-tools/>) ([Table 1](#t1-copd-13-1735){ref-type="table"}). Mass determination was carried out using a MALDI-TOF mass spectrometer (Agena Biosciences Inc.), and the MassAR-RAY Type 4.0 software (Agena Biosciences Inc.) was used for data acquisition.

Covariate assessment
--------------------

Demographic characteristics and COPD risk factors (age, sex, height, weight, smoking status, age at first cigarette, number of cigarettes/day, cooking and heating with coal stove, family history of lung disease, and childhood history of respiratory disease) were obtained using a questionnaire designed for this specific population. All participants were personally interviewed by trained interviewers.

The smoking status was defined as follows:[@b25-copd-13-1735] subjects who had smoked \>20 packs of cigarettes in a lifetime or 1 cigarette/d for a year were regarded as ever smokers (current or former); otherwise, they were classified as never smokers. Smokers who were still smoking at the time of the interview were considered as current smokers, and those who had quit (for at least 30 days before the interview) were former smokers.[@b26-copd-13-1735] Pack-years were calculated in smokers by multiplying the average number of cigarettes smoked per day by the number of years of smoking and by dividing by 20 cigarettes/pack. Participants were classified as follows: 0, 0--20 and \>20 pack-years. Cooking and heating with coal stove meant that the participants were using coal as domestic fuel. Body mass index (BMI) was calculated by dividing the weight (in kilograms) by the squared height (in meters).

Statistical analysis
--------------------

Continuous data were presented as mean ± standard deviation, and categorical data were presented as frequency or percentage. The differences in the distributions of demographic characteristics, selected variables, and genotypes between the two groups were analyzed with Student's *t*-test or the chi-square test, as appropriate. HWE for each SNP was tested using the chi-square test in the control group.

Unconditional logistic regression analyses without or with adjustment for the covariates (age, sex, BMI, smoking status, pack-years, coal consumption, pulmonary problems in childhood, and family history of pulmonary diseases) were used to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for evaluating the effect of each SNP on COPD risk. Then, genetic variants were assessed using different genetic models (additive, dominant, and recessive). The subgroup analyses according to the abovementioned covariates were performed using stratified models.

All analyses were performed with R (<http://www.R-project.org>, The R Foundation) and Empowerstats (<http://www.empowerstats.com>, X&Y Solutions, Inc., Boston, MA, USA). Two-sided *P*-values \<0.05 were considered statistically significant.

Results
=======

Characteristics of the participants
-----------------------------------

[Figure 1](#f1-copd-13-1735){ref-type="fig"} presents the study flowchart; 491 patients with COPD and 611 controls were included. Their characteristics are presented in [Table 2](#t2-copd-13-1735){ref-type="table"}. There were no differences in age, sex, coal use, and childhood pulmonary problems between the two groups (all *P*\>0.05). Compared with the control group, the COPD group had significantly more smokers (*P*\<0.0001), more pack-years smoked (*P*\<0.0001), higher family history of pulmonary diseases (*P*=0.03), and lower BMI (*P*\<0.0001). Among the patients with COPD, 25.9%, 45.8%, 21.6%, and 6.7% were classified as GOLD stages I, II, III, and IV, respectively, according to airflow limitation (FEV~1~%pre levels).

Association between SNPs and COPD susceptibility
------------------------------------------------

The information about the selected SNPs is shown in [Table 3](#t3-copd-13-1735){ref-type="table"}. All of the SNPs were distributed within the parameters of HWE for the control population (*P*\>0.05). The call rates during the genotyping of these SNPs were all above 95%.

The frequencies of the SNPs in the COPD and control groups are shown in [Table 4](#t4-copd-13-1735){ref-type="table"}. The frequencies of rs17014601 T\>C and rs16969858 C\>T were significantly different between the two groups (*P*=0.0005 and *P*=0.03, respectively). When considering the rs17014601 SNP in the *FAM13A* gene, compared with the TT genotype, the CT genotype was associated with an increased risk of COPD (non-adjusted OR=1.65, 95% CI=1.28--2.13). The association was stable in the age- and sex-adjusted analysis (adjusted OR=1.66, 95% CI=1.29--2.15), and even after adjusting for more covariates (age, sex, BMI, smoking status, pack-years smoked, coal use, family history of lung disease, and childhood history of respiratory disease) (adjusted OR=1.76, 95% CI=1.33--2.32).

Five genetic models (additive, heterozygote, homozygote, dominant, and recessive) were used to analyze the associations between the variants and risk of COPD with and without adjustments for covariates ([Table 5](#t5-copd-13-1735){ref-type="table"}). The rs17014601 T\>C SNP fitted the additive model, showing a significantly increased risk of COPD in the presence of a C allele, in a dose-dependent manner, and after adjustment for age, sex, and other covariates (adjusted OR=1.36, 95% CI=1.11--1.67, *P*=0.0028). The rs17014601 CT genotype was associated with an increased risk of COPD based on the heterozygote model (adjusted OR=1.76; 95% CI=1.33--2.32; *P*=0.0001) and dominant model (adjusted OR=1.67; 95% CI=1.28--2.18; *P*=0.0001).

No associations between the other SNPs and COPD were observed in the multivariate logistic regression analyses and genetic models.

Stratification analysis
-----------------------

The association between variant genotypes and COPD risk was further evaluated using analyses stratified by age, sex, BMI, smoking status, pack-years smoked, coal use, family history of lung disease, and childhood history of respiratory disease ([Table 6](#t6-copd-13-1735){ref-type="table"}). The FAM13A rs17014601 CT genotype was associated with an increased COPD risk in never smokers (adjusted OR=1.97, 95% CI=1.05--3.72, *P*=0.0356) and 0 pack-years smoked (adjusted OR=2.06, 95% CI=1.44--2.96, *P*=0.0001), when compared to the respective reference groups.

Stratified analysis of association between the rs16969858 SNP and COPD risk provided no statistically significant result ([Table S1](#SD1-copd-13-1735){ref-type="supplementary-material"}). There was no effect of the rs16969858 SNP genotype in different smoking status ([Table S2](#SD2-copd-13-1735){ref-type="supplementary-material"}). There was no effect of the rs16969858 SNP genotype in different smoking status according to the dominant and recessive models ([Table S3](#SD3-copd-13-1735){ref-type="supplementary-material"}). There was no effect of the rs17014601 SNP in different smoking statuses ([Table S4](#SD4-copd-13-1735){ref-type="supplementary-material"}), nor according to the dominant and recessive models ([Table S5](#SD5-copd-13-1735){ref-type="supplementary-material"}).

Discussion
==========

In the present population-based case-control study, we investigated the potential associations of FAM13A rs17014601 T\>C, rs16996144 G\>A, and rs1870339 C\>G and IREB2 rs2009746 A\>G, rs16969858 C\>T, rs2656065 G\>A, and rs3743079 C\>T SNPs with COPD susceptibility in a Chinese rural population. We found that FAM13A rs17014601 had an independent effect on the COPD risk. The C allele in the FAM13A rs17014601 was significantly associated with COPD risk or occurrence in a Chinese rural population.

FAM13A on chromosome 4q22 has been consistently associated with COPD by GWAS. Among many tested SNPs, the rs7671167 SNP in FAM13A is most highly associated with COPD in Caucasians[@b7-copd-13-1735],[@b27-copd-13-1735],[@b28-copd-13-1735] and Asians, especially in Chinese.[@b29-copd-13-1735] Indeed, Xie et al[@b29-copd-13-1735] confirmed that the FAM13A rs7671167 SNP was associated with COPD risk in a Chinese Han population and that rs7671167 was related to lung function decline. In addition, Guo et al[@b30-copd-13-1735] reported that the frequency of the rs2869967 C allele was significantly increased in Chinese patients with COPD,[@b30-copd-13-1735] and Wang et al[@b31-copd-13-1735] showed that five FAM13A SNPs (rs7671167, rs2869966, rs2869967, rs2045517, and rs6830970) were associated with the FEV~1~/FVC ratio in all subjects and that rs6830970 was associated with the FEV~1~/FVC ratio in the COPD subset. Furthermore, the FAM13A locus is apparently not influenced by smoking.[@b4-copd-13-1735] van der Plaat et al[@b32-copd-13-1735] suggested that the FAM13A loci (including rs6849143) are significantly associated with lung function measurements in never smokers.

In the present study, we found that a new FAM13A variant contributed to COPD risk in a Chinese rural population. Indeed, rs17014601 was significantly associated with an increased risk of COPD. In People's Republic of China, COPD is more common among rural residents compared with urban residents,[@b2-copd-13-1735] probably because of a number of environmental risk factors such as old age, smoking, coal use, infection, and low body mass index. Ningxia is an agricultural region in Northwestern China. Coal stove cooking and winter coal heating are very common. One advantage of our study is that we conducted an investigation of the possible COPD risk factors in individuals who were not yet treated for any lung disease. Then, we adjusted these associations according to known risk factors for COPD, including coal use. The association between rs17014601 and COPD remained significant after adjusting for the confounding factors. In addition, stratified analyses showed that never smokers had a higher risk of COPD in association with FAM13A rs17014601 compared with the whole cohort. This is the first report of the association between the FAM13A rs17014601 and COPD risk, but the results have to be confirmed by additional studies.

The exact biological functions of FAM13A are still unknown. The RhoGAP domain in the exon region may be related to COPD.[@b13-copd-13-1735] Rho GTPases are key regulators of cytoskeletal dynamics involved in pulmonary endothelial barrier functions, and have been shown to be dysregulated in several lung diseases.[@b33-copd-13-1735] It is probable that genetic variations of FAM13A may affect Rho GTPases activity and the cellular pathways associated with FAM13A, hereby contributing to lung disease. The most significant SNPs in FAM13A have been found in non-coding regions downstream of the RhoGAP domain and are associated with *FAM13A* gene expression levels.[@b7-copd-13-1735] Recently, the biological function of FAM13A in emphysema development has been explored: Jiang et al[@b11-copd-13-1735] reported the expression of the FAM13A protein in airways, alveolar epithelial cells, and alveolar macrophages. FAM13A knockout mouse models are less susceptible to develop emphysema.[@b11-copd-13-1735] In vitro experiments showed that FAM13A interacts with PP2A and promotes the degradation of β-catenin in bronchial epithelial cells, inhibiting the activation of the Wnt pathway.[@b10-copd-13-1735] Moreover, metabolic regulation may be another mechanism by which FAM13A promotes CS-induced emphysema.[@b34-copd-13-1735] Indeed, FAM13A promotes fatty acid oxidation (FAO) and subsequent increases in ROS, possibly by interacting with Sirtuin 1 (SIRT1) and increasing the expression of CPT1A, a key mitochondrial enzyme for the FAO pathway, thereby enhancing FAO. These findings suggest that the impact of FAM13A on COPD could be independent from smoke exposure.

A previous study in Caucasians showed that IREB2 polymorphisms had an effect of COPD susceptibility, independently from smoking.[@b27-copd-13-1735] A Russian study showed associations between the rs13180 SNP in IREB2 and COPD and lung function in the Tatar population.[@b35-copd-13-1735] A study from Poland suggests that the rs2568494 SNP in IREB2 was not associated with COPD, but with lung cancer.[@b28-copd-13-1735] In the present study, the rs16969858 SNP in the *IREB2* gene was significantly associated with COPD only in the univariate analysis, and multivariate analysis did not show any association. These discrepancies may be due to the selection of the SNPs being studied, as well as to the interactions with other environmental and genetic factors. Indeed, the rs16969858 SNP is an intronic SNP that could cause dysfunction because of differential splicing. A recent genome-wide bioinformatics study suggested that there were no differences in gene expression of *IREB2* and *FAM13A*, but that the expression of these genes was dependent on the interactions of genes.[@b36-copd-13-1735] This suggests new research avenues and expression studies in lung tissues should be performed.

There are some limitations in the present study that should be addressed. The number of COPD cases was limited. Larger scale studies are needed in different populations to validate the result. Although we were able to identify associations, we were not able to identify the causal mechanisms. This is the first study on the association between rs17014601 and COPD. The Han ethnicity was selected because it is the major ethnic group in China. Nevertheless, we agree that other ethnic groups will have to be studied. In addition, the Han populations that were enrolled in the COPD Susceptibility Study were mainly from southern China. In the present study, we included Chinese Han people from Northwest China and it is possible that there are genetic differences between South and North China.[@b37-copd-13-1735] Additional studies are still necessary to understand the genetics of COPD.

Conclusion
==========

The present study strongly suggests an association between the *FAM13A* gene and COPD in Chinese rural patients. Further studies are required to elucidate the functional roles of these variants, which may have an impact on the management of lung diseases.

Supplementary materials
=======================

###### 

Stratified analysis of the association between the rs16969858 SNP and COPD risk

  Factors                                Cases   Controls   Adjusted[a](#tfn14-copd-13-1735){ref-type="table-fn"}   *P*-value                                      
  -------------------------------------- ------- ---------- ------------------------------------------------------- ----------- ----- ----- ---------------------- --------
  Age (years)                                                                                                                                                      
   ≤60                                   1       10         54                                                      0           21    77    0.861 (0.350--2.119)   0.7446
   \>60                                  4       78         336                                                     6           90    402   0.984 (0.686--1.413)   0.9315
  Sex                                                                                                                                                              
   Male                                  5       66         269                                                     3           77    322   1.051 (0.709--1.558)   0.8039
   Female                                0       22         121                                                     3           34    157   0.905 (0.462--1.776)   0.7725
  Smoking status                                                                                                                                                   
   Current                               1       29         150                                                     0           21    102   2.182 (0.969--4.914)   0.0597
   Former                                0       19         69                                                      1           29    130   0.717 (0.339--1.515)   0.3828
   Never                                 4       40         171                                                     5           59    249   0.985 (0.619--1.568)   0.9497
  Pack-years smoked                                                                                                                                                
   ≥20                                   1       35         153                                                     1           27    107   1.299 (0.636--2.651)   0.4726
   \<20                                  1       12         64                                                      0           25    127   0.882 (0.393--1.982)   0.7619
   0                                     3       41         173                                                     5           59    244   0.920 (0.583--1.453)   0.7206
  BMI                                                                                                                                                              
   \<18.5                                1       4          44                                                      1           7     27    0.12 (0.01--1.00)      0.0504
   18.5--24.9                            3       68         251                                                     1           72    294   1.074 (0.725--1.592)   0.7216
   ≥25.0                                 1       16         95                                                      4           32    157   0.916 (0.459--1.827)   0.8038
  Coal consumption                                                                                                                                                 
   Yes                                   4       76         318                                                     5           95    379   1.021 (0.709--1.469)   0.9128
   No                                    1       12         72                                                      1           16    100   0.771 (0.264--2.248)   0.6336
  Pulmonary problems in childhood                                                                                                                                  
   Yes                                   1       4          33                                                      1           8     41    1.018 (0.241--4.295)   0.9803
   No                                    4       83         355                                                     5           103   438   1.032 (0.739--1.441)   0.8526
  Family history of pulmonary diseases                                                                                                                             
   Yes                                   2       9          32                                                      1           8     23    0.808 (0.214--3.056)   0.7537
   No                                    3       79         356                                                     5           103   455   1.026 (0.733--1.437)   0.8801

**Notes:**

Adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease. In each case, the model was not adjusted for the stratification variable.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; BMI, body mass index.

###### 

Effect of the rs16969858 SNP genotype in different smoking statuses

  Smoking status              Genotype   Case n=483   Control n=596   Crude OR (95% CI)          Adjustment I model OR (95% CI)   Adjustment II model OR (95% CI)
  --------------------------- ---------- ------------ --------------- -------------------------- -------------------------------- ---------------------------------
  Never                       CC         171          249             1                          1                                1
  Never                       TC         40           59              0.971 (0.622--1.518)       0.945 (0.603--1.482)             0.874 (0.554--1.379)
  Never                       TT         4            5               1.146 (0.303--4.331)       1.213 (0.319--4.620)             1.377 (0.356--5.322)
  Former                      CC         69           130             0.760 (0.535--1.08)        0.747 (0.515--1.083)             0.682 (0.466--0.998)
  Former                      TC         19           29              0.939 (0.510--1.729)       0.935 (0.498--1.753)             0.918 (0.485--1.735)
  Former                      TT         0            1               0.0 (0.000, Inf)           0.000 (0.000, Inf)               0.000 (0.000, Inf)
  Current                     CC         150          102             2.107 (1.532--2.897)       2.049 (1.478--2.841)             2.043 (1.456--0.866)
  Current                     TC         29           21              1.979 (1.092--3.586)       1.896 (1.034--3.476)             1.748 (0.938--3.255)
  Current                     TT         1            0               1116446.183 (0.000, Inf)   844979.151 (0.000, Inf)          751029.731 (0.000, Inf)
  *P*-value for interaction   0.6694     0.6999       0.6244                                                                      

**Notes:** Adjustment I model was adjusted for age and sex. Adjustment II model was adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease. Inf, the sample size is too small.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; BMI, body mass index.

###### 

Effect of the rs16969858 SNP according to different smoking statuses and the dominant and recessive models

  Smoking status              Genotype   Case n=483   Control n=596   Crude OR (95% CI)      Adjustment I model OR (95% CI)   Adjustment II model OR (95% CI)
  --------------------------- ---------- ------------ --------------- ---------------------- -------------------------------- ---------------------------------
  Never                       CC         171          249             1                      1                                1
  Never                       TC+TT      44           64              0.985 (0.640--1.515)   0.965 (0.625--1.489)             0.907 (0.585--1.408)
  Former                      CC         69           130             0.760 (0.535--1.08)    0.746 (0.514--1.082)             0.681 (0.465--0.997)
  Former                      TC+TT      19           30              0.907 (0.495--1.665)   0.906 (0.485--1.693)             0.893 (0.474--1.683)
  Current                     CC         150          102             2.107 (1.532--2.897)   2.048 (1.477--2.840)             2.041 (1.455--2.864)
  Current                     TC+TT      30           21              2.047 (1.134--3.696)   1.952 (1.068--3.566)             1.799 (0.970--3.336)
  *P*-value for interaction   0.8718     0.8258       0.6148                                                                  

**Notes:** Adjustment I model was adjusted for age and sex. Adjustment II model was adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease. rs16969858 C\>T: The sample size of TT is too small.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; BMI, body mass index.

###### 

Effect of the rs17014601 SNP in different smoking statuses

  Smoking status              Genotype   Case n=479   Control n=596   Crude OR (95% CI)      Adjustment I model OR (95% CI)   Adjustment II model OR (95% CI)
  --------------------------- ---------- ------------ --------------- ---------------------- -------------------------------- ---------------------------------
  Never                       TT         81           172             1                      1                                1
  Never                       CT         107          109             2.084 (1.432--3.034)   2.094 (1.438--3.051)             1.948 (1.328--2.858)
  Never                       CC         24           26              1.960 (1.06--3.624)    1.987 (1.074--3.677)             1.896 (1.012--3.554)
  Former                      TT         36           80              0.956 (0.595--1.535)   0.906 (0.557--1.474)             0.804 (0.490--1.319)
  Former                      CT         46           66              1.480 (0.934--2.344)   1.398 (0.871--2.243)             1.305 (0.807--2.109)
  Former                      CC         7            17              0.874 (0.349--2.192)   0.827 (0.327--2.095)             0.753 (0.292--1.944)
  Current                     TT         86           67              2.726 (1.801--4.125)   2.626 (1.728--3.992)             2.512 (1.626--3.882)
  Current                     CT         79           46              3.647 (2.327--5.716)   3.533 (2.245--5.558)             3.445 (2.173--5.461)
  Current                     CC         13           10              2.760 (1.162--6.561)   2.690 (1.128--6.416)             2.638 (1.087--6.401)
  *P*-value for interaction   0.4450     0.4385       0.6186                                                                  

**Notes:** Adjustment I model was adjusted for age and sex. Adjustment II model was adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; BMI, body mass index.

###### 

Effect of the rs17014601 SNP in different smoking statuses according to the dominant and recessive models

  Smoking status              Genotype   Case n=479   Control n=596   Crude OR (95% CI)      Adjustment I model OR (95% CI)   Adjustment II model OR (95% CI)
  --------------------------- ---------- ------------ --------------- ---------------------- -------------------------------- ---------------------------------
  Never                       TT         81           172             1                      1                                1
  Never                       CT+CC      131          135             2.061 (1.442--2.945)   2.073 (1.449--2.965)             1.937 (1.345--2.789)
  Former                      TT         36           80              0.956 (0.595--1.535)   0.908 (0.558--1.477)             0.805 (0.491--1.322)
  Former                      CT+CC      53           83              1.356 (0.878--2.093)   1.283 (0.819--2.011)             1.195 (0.757--1.887)
  Current                     TT         86           67              2.726 (1.801--0.125)   2.627 (1.728--3.993)             2.515 (1.628--3.887)
  Current                     CT+CC      92           56              3.489 (2.282--5.333)   3.385 (2.205--5.197)             3.306 (2.136--5.117)
  *P*-value for interaction   0.2256     0.2231       0.4110                                                                  

**Notes:** Adjustment I model was adjusted for age and sex. Adjustment II model was adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; BMI, body mass index.

We would like to thank the individuals who participated in this study, as well as the staff who helped complete the questionnaires and collect blood samples: Xiulan Wu, Zhanfu Yao, and Zhonggang Zhao (from the Center for Disease Control and Prevention in Qingtongxia city, Ningxia Hui Autonomous Region, People's Republic of China); Xingyan Lu and Liankai Chen (from the Ye Sheng town hospital in Qingtongxia City, Ningxia Hui Autonomous Region, People's Republic of China); and Tao Ma (from the Qingtongxia City Hospital, Ningxia Hui Autonomous Region, People's Republic of China). This study was funded by the Ningxia Science and Technology Huimin project (Grant No 2014KJHM05), the Ningxia Medical University scientific research project (Grant No 2001210203), and the National Natural Science Foundation of China (Grant No 81760011).

**Disclosure**

The authors report no conflicts of interest in this work.

![Study flowchart.\
**Abbreviation:** COPD, chronic obstructive pulmonary disease.](copd-13-1735Fig1){#f1-copd-13-1735}

###### 

SNPs and primers

  SNP ID       First PCR primer                        Second PCR primer
  ------------ --------------------------------------- ---------------------------------------
  rs17014601   5′-ACGTTGGATGCTCAAAACATAAAGTGCAAC-3′    5′-ACGTTGGATGTACCTCCCCAGTTGGCAAG-3′
  rs16996144   5′-ACGTTGGATGAAACCTTTGACTCTGGCCTC-3′    5′-ACGTTGGATGTCCTGCAGATCATAGAGGAC-3′
  rs1870339    5′-ACGTTGGATGGTTAAGACCTATTCAACTTCC-3′   5′-ACGTTGGATGGAGTTATACTGTAAAACACAC-3′
  rs2009746    5′-ACGTTGGATGGAGCACAGAAGTATAAAATC-3′    5′-ACGTTGGATGAAACGCTCCTGTGAAATAAC-3′
  rs16969858   5′-ACGTTGGATGAGTGAAGAAGGATTTATTG-3′     5′-ACGTTGGATGTCTGGGCCACCACCATTTTC-3′
  rs2656065    5′-ACGTTGGATGCTTAGTGTTGTGTATTTCCC-3′    5′-ACGTTGGATGGATAACTGTAATCCTTTTTC-3′
  rs3743079    5′-ACGTTGGATGCTGCCATGGTCCATCTTCAT-3′    5′-ACGTTGGATGCCTTAGTCTAACTGCAAGGG-3′

**Abbreviation:** SNPs, single-nucleotide polymorphisms.

###### 

Characteristics of the subjects

  Variables                                     Cases (n=491)   Controls (n=611)   *P*-value
  --------------------------------------------- --------------- ------------------ -----------
  Age (years) (mean ± SD)                       69.0±7.4        68.1±7.5           0.0660
  Male subjects, n (%)                          347 (70.7)      410 (67.1)         0.2040
  Body mass index (kg/m^2^) (mean ± SD)         22.6±3.5        23.5±3.4           \<0.0001
  Smoking status at baseline, n (%)                                                \<0.0001
   Current                                      182 (37.1)      125 (20.6)         
   Former                                       90 (18.3)       165 (27.2)         
   Never                                        219 (44.6)      316 (52.2)         
  Pack-years smoked (mean ± SD)                 21.0±26.7       11.7±19.1          \<0.0001
  Coal consumption, n (%)                       404 (82.3)      492 (80.5)         0.4570
  Pulmonary problems in childhood, n (%)        38 (7.8)        51 (8.4)           0.7290
  Family history of pulmonary diseases, n (%)   42 (8.6)        32 (5.3)           0.0280
  Lung function (mean ± SD)                                                        
   FEV~1~ (L)                                   1.57±0.59       2.21±0.56          \<0.0001
   FEV~1~, %predicted (%)                       64.0±21.6       85.7±13.4          \<0.0001
   FVC (L)                                      2.57±0.85       2.78±0.72          \<0.0001
   FEV~1~/FVC (%)                               60.7±8.3        79.5±5.4           \<0.0001
  GOLD stage                                                                       
   1                                            127 (25.9)                         
   2                                            225 (45.8)                         
   3                                            106 (21.6)                         
   4                                            33 (6.7)                           

###### 

Characteristics of the SNPs in this study

  SNP no       Gene       Loc       Category   Call rate (%)   MAF in the control group   GENO     *P*-value HWE                 
  ------------ ---------- --------- ---------- --------------- -------------------------- -------- --------------- ------------- --------
  rs17014601   *FAM13A*   4q22.1    Intron     97.1            C                          0.1599   0.2698          49/229/328    0.1248
  rs16996144   *FAM13A*   4q22.1    Intron     97.8            A                          0.4948   0.4562          125/302/178   0.9738
  rs1870339    *FAM13A*   4q22.1    Intron     98.2            G                          0.3822   0.2882          55/241/313    0.1108
  rs2009746    *IREB2*    15q25.1   Intron     97.4            G                          0.2308   0.1203          10/125/469    0.0633
  rs16969858   *IREB2*    15q25.1   Intron     98.1            T                          0.0172   0.1018          6/112/491     0.9488
  rs2656065    *IREB2*    15q25.1   Intron     97.7            A                          0.3552   0.2273          30/216/360    0.9617
  rs3743079    *IREB2*    15q25.1   3′ UTR     98.0            T                          0.1486   0.1310          12/135/460    0.3134

**Abbreviations:** SNPs, single-nucleotide polymorphisms; MAF, minor allele frequency; 1000G, 1000 genomes data; HWE, Hardy-Weinberg equilibrium; Loc, location; GENO, genotype; Our, data in our study.

###### 

Association between FAM13A and IREB2 SNPs and risk of COPD

  Genotype          Genotype frequency   *P*-value[a](#tfn3-copd-13-1735){ref-type="table-fn"}   Non-adjusted model OR (95% CI)   Adjusted OR (95% CI)                       
  ----------------- -------------------- ------------------------------------------------------- -------------------------------- ---------------------- ------------------- -------------------
  Total n           N=491                N=611                                                                                                                               
  rs17014601T\>C    n=479                n=596                                                   0.0005                                                                      
   TT               203 (42.4)           321 (53.9)                                                                               1.00 (ref)             1.00 (ref)          1.00 (ref)
   CT               232 (48.4)           222 (37.3)                                                                               1.65 (1.28--2.13)      1.66 (1.29--2.15)   1.76 (1.33--2.32)
   CC               44 (9.2)             53 (8.9)                                                                                 1.31 (0.85--2.03)      1.33 (0.86--2.07)   1.34 (0.83--2.17)
  rs16996144G\> A   n=480                n=594                                                   0.4585                                                                      
   GG               125 (26.0)           174 (29.3)                                                                               1.00 (ref)             1.00 (ref)          1.00 (ref)
   AG               253 (52.7)           294 (49.5)                                                                               1.20 (0.90--1.59)      1.20 (0.90--1.59)   1.15 (0.84--1.57)
   AA               102 (21.3)           126 (21.2)                                                                               1.13 (0.80--1.60)      1.12 (0.79--1.59)   1.22 (0.83--1.78)
  rs1870339C\>G     n=484                n=597                                                   0.3349                                                                      
   CC               255 (52.7)           304 (50.9)                                                                               1.00 (ref)             1.00 (ref)          1.00 (ref)
   GC               181 (37.4)           232 (38.9)                                                                               0.93 (0.72--1.20)      0.92 (0.71--1.19)   0.92 (0.70--1.22)
   GG               48 (9.9)             61 (10.2)                                                                                0.94 (0.62--1.42)      0.93 (0.62--1.41)   1.01 (0.65--1.57)
  rs2009746 A\>G    n=485                n=603                                                   0.3930                                                                      
   AA               371 (76.5)           456 (75.6)                                                                               1.00 (ref)             1.00 (ref)          1.00 (ref)
   GA               101 (20.8)           127 (21.1)                                                                               0.98 (0.73--1.31)      0.98 (0.73--1.32)   0.93 (0.67--1.28)
   GG               13 (2.7)             20 (3.3)                                                                                 0.80 (0.39--1.63)      0.79 (0.39--1.62)   0.96 (0.45--2.07)
  rs16969858 C\>T   n=483                n=596                                                   0.0305                                                                      
   CC               390 (80.8)           479 (80.4)                                                                               1.00 (ref)             1.00 (ref)          1.00 (ref)
   TC               88 (18.2)            111 (18.6)                                                                               0.97 (0.71--1.33)      0.97 (0.71--1.32)   0.96 (0.69--1.35)
   TT               5 (1.0)              6 (1.0)                                                                                  1.02 (0.31--3.38)      0.99 (0.30--3.28)   1.17 (0.34--4.02)
  rs2656065 G\>A    n=470                n=590                                                   0.5889                                                                      
   GG               292 (62.1)           348 (59.0)                                                                               1.00 (ref)             1.00 (ref)          1.00 (ref)
   AG               155 (33.0)           211 (35.8)                                                                               0.88 (0.68--1.13)      0.88 (0.68--1.14)   0.87 (0.66--1.15)
   AA               23 (4.9)             31 (5.3)                                                                                 0.88 (0.50--1.55)      0.86 (0.49--1.51)   0.88 (0.48--1.64)
  rs3743079 C\>T    n=466                n=581                                                   0.5210                                                                      
   CC               345 (74.0)           443 (76.3)                                                                               1.00 (ref)             1.00 (ref)          1.00 (ref)
   TC               106 (22.8)           125 (21.5)                                                                               1.09 (0.81--1.46)      1.11 (0.82--1.49)   1.14 (0.83--1.57)
   TT               15 (3.2)             13 (2.2)                                                                                 1.48 (0.70--3.16)      1.50 (0.70--3.19)   1.20 (0.52--2.74)

**Notes:**

*P*-values of a two-sided *χ*^2^ test, *α*=0.05.

Adjusted for age and sex.

Adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; BMI, body mass index.

###### 

Association between rs17014601 and risk of COPD in different inheritance models

  Model          Genotypes   Cases n (%)   Controls n (%)   Non-adjusted model   Adjustment I model   Adjustment II model                                
  -------------- ----------- ------------- ---------------- -------------------- -------------------- --------------------- -------- ------------------- --------
  Additive                                                  1.32 (1.10--1.59)    0.0032               1.33 (1.11--1.61)     0.0025   1.36 (1.11--1.67)   0.0028
                 TT          203 (42.4)    321 (53.9)       1                                         1                              1                   
  Heterozygote   CT          232 (48.4)    222 (37.3)       1.65 (1.28--2.13)    0.0001               1.66 (1.29--2.15)     0.0001   1.76 (1.33--2.32)   0.0001
  Homozygote     CC          44 (9.2)      53 (8.9)         1.31 (0.85--2.03)    0.2219               1.33 (0.86--2.07)     0.1967   1.34 (0.83--2.17)   0.2245
  Dominant       CT+CC       276 (57.6)    275 (46.1)       1.59 (1.25--2.02)    0.0002               1.60 (1.26--2.04)     0.0001   1.67 (1.28--2.18)   0.0001
  Recessive      TT+CT       435 (90.8)    543 (91.1)       1                                         1                              1                   
                 CC          44 (9.2)      53 (8.9)         1.04 (0.68--1.58)    0.8676               1.05 (0.69--1.60)     0.8230   1.03 (0.65--1.62)   0.9014

**Notes:** The Benjamini and Hochberg FDR method was used to adjust the multiple hypothesis tests, standard *α*=0.05.

Unadjusted model.

Adjustment I model was adjusted for age and sex.

Adjustment II model was adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; FDR, false discovery rate; BMI, body mass index.

###### 

Stratified analysis of the association between the rs17014601 SNP and COPD risk

  Factors                                Cases   Controls   Adjusted[a](#tfn12-copd-13-1735){ref-type="table-fn"}   *P*-value                                    
  -------------------------------------- ------- ---------- ------------------------------------------------------- ----------- ----- ----- -------------------- --------
  Age (years)                                                                                                                                                    
   ≤60                                   10      30         26                                                      10          34    54    2.75 (0.79--9.51)    0.1105
   \>60                                  34      202        177                                                     43          188   267   1.16 (0.68--1.97)    0.5951
  Sex                                                                                                                                                            
   Male                                  28      259        148                                                     38          149   215   1.19 (0.67--2.13)    0.5515
   Female                                16      73         55                                                      15          73    106   2.24 (0.93--5.38)    0.0718
  Smoking status                                                                                                                                                 
   Current                               13      79         86                                                      10          46    67    0.97 (0.31--3.02)    0.9533
   Former                                7       46         36                                                      17          66    80    1.54 (0.50--4.69)    0.4506
   Never                                 24      107        81                                                      26          109   172   1.97 (1.05--3.72)    0.0356
  Pack-years smoked                                                                                                                                              
   ≥20                                   15      94         80                                                      14          51    71    1.50 (0.94--2.39)    0.0898
   \<20                                  5       31         40                                                      13          62    78    0.89 (0.51--1.56)    0.6836
   0                                     24      107        83                                                      26          109   172   2.06 (1.44--2.96)    0.0001
  BMI                                                                                                                                                            
   \<18.5                                6       23         22                                                      3           10    21    3.34 (0.37--29.95)   0.2805
   18.5--24.9                            30      168        128                                                     34          141   193   1.52 (0.85--2.73)    0.1576
   ≥25.0                                 8       48         53                                                      16          71    107   0.75 (0.27--2.13)    0.5889
  Coal consumption                                                                                                                                               
   Yes                                   38      193        164                                                     40          186   254   1.66 (0.98--2.81)    0.0616
   No                                    6       39         39                                                      13          36    67    0.96 (0.15--6.25)    0.9693
  Pulmonary problems in childhood                                                                                                                                
   Yes                                   2       21         15                                                      2           22    24    0.47 (0.05--4.83)    0.5254
   No                                    42      209        187                                                     48          200   297   1.39 (0.86--2.27)    0.1822
  Family history of pulmonary diseases                                                                                                                           
   Yes                                   2       20         20                                                      2           10    19    1.41 (0.12--17.12)   0.7854
   No                                    41      211        183                                                     51          212   302   1.36 (0.83--2.22)    0.2200

**Notes:**

Adjusted for age, sex, BMI, smoking status, pack-years smoked, coal consumption, family history of lung disease, and childhood history of respiratory disease. In each case, the model was not adjusted for the stratification variable.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; BMI, body mass index.
